Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Lens Method Analyzes Tears for Early Disease Detection

By LabMedica International staff writers
Posted on 20 Dec 2024

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues. Tears, in particular, are well-suited for detecting eye diseases such as glaucoma and macular degeneration, but they can also help identify systemic conditions like breast cancer and Alzheimer's disease. The challenge, however, is that collecting tears is difficult. Existing tear sampling methods can be uncomfortable, irritating to the eye, and typically yield reflex tears, which are less useful for disease detection. Now, researchers have developed an innovative technique using soft contact lenses to collect proteins from basal tears, offering a more efficient method for early disease detection.

While reflex tears are easily triggered by irritation, they are unlikely to contain the proteins needed for disease detection. These tears would dilute the indicator proteins that could point to a health issue. To avoid this, researchers at Brigham Young University (Provo, UT, USA) proposed a gentler approach: using soft contact lenses that naturally absorb proteins from the eye. Their tests showed that lenses made from the hydrogel material Etafilcon-A collected the highest protein levels without causing irritation.

In experiments, volunteers wore the contact lenses for just five minutes, and the lenses absorbed nearly the same range of proteins as traditional methods, but with significantly less discomfort. This new approach, as described in the study published in Clinical Proteomics, also allows patients to collect their own tears, removing the need for a trained optometrist. The research team is currently conducting further clinical trials to link specific tear proteins with diseases like macular degeneration and cancer. Their long-term goal is to make this method available in optometrists' and oncologists' offices, providing an easy and non-invasive way to detect early signs of various conditions.

“How many people could be helped if doctors could catch diseases before symptoms develop? With this new lens method, we could potentially screen for a range of health issues from analyzing tears,” said former grad student Robert Roden. “This project is very powerful in its scope. Any disease that your blood touches has the potential to show up in your tears. Hopefully this sampling can turn into a routine screening.”

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.